Two New Trials of Merck ’s KEYTRUDA® (pembrolizumab) as Monotherapy and in Combination with Chemotherapy for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer to be Presented During Presidential Session at ESMO 2016

Dateline City: KENILWORTH, N.J. Results from KEYNOTE-024, which Studied KEYTRUDA Compared to Chemotherapy in Patients with High Levels of PD-L1 Expression, and KEYNOTE-021G, which Studied KEYTRUDA in Combination with Chemotherapy Compared to Chemotherapy Alone in Patients Regardless of PD-L1 Expression, to be Presented Comprehensive Data from Merck ’s Industry-Leading Immuno-Oncology Clinical Development Program to be Presented, with New Data in 12 CancersKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that extensive data on KEYTRUDA® (pembrolizumab), the company ’s anti-PD-1 therapy, have been accepted for presentation at the European Society for Medical Oncology (ESMO) 2016 Congress in Copenhagen, Denmark, Oct. 7 – 11. In total, findings from 30 studies in 12 cancers from Merck’s industry-leading clinical development progr am for KEYTRUDA – both as monotherapy and in combination – will be presented at this year’s ESMO.Language: EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558Kim Hamilton, 908-740-1863orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898Ticker Slug:Ticker:MRKExchange:NYSEread more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News Source Type: news